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Pathophysiology and Treatment of Hepatitis
B and C Infections in Patients With End-Stage
Renal Disease
Vivek Soi, Chantale Daifi, Jerry Yee, and Elizabeth Adams
An in-depth understanding of viral hepatitis is important to the care of patients with end-stage renal disease undergoing hemodialysis. Both hepatitis B and C viruses are acquired through hematogenous spread and can lead to horizontal transmission.
Concurrent hepatic and renal injuries have ominous outcomes with significant morbidity. Hepatitis B incidence has decreased
through practices including vaccination of nonimmune individuals and isolation of patients with the disease. The pathogenesis
of hepatitis B leads to various symptoms and serologic changes with unique temporal associations dictating an acute or chronic
presentation. Chronic hepatitis B develops when there is persistence of surface antigen for more than 6 months. Occult hepatitis
B is an enigmatic form of the chronic disease where viral DNA is present despite the patient remaining seronegative. Nucleoside
analogs are used as a treatment for individuals with hepatitis B who have comorbid CKD; however, the mainstay of infection
control relies on immunization. Hepatitis C, an RNA virus, has increased in prevalence. Strict universal precautions with sound
infection-control practices are important to prevent seroconversion. Recent therapeutic advances involving the development of
direct-acting antiviral agents have broadened treatment options for patients with renal impairment and hepatitis C, offering the
potential for a definitive cure. Controversy on the timeliness of treatment for transplant options has also risen with the advent of
these newer therapies. We review the epidemiology, pathophysiology, and updates in treatment of these viral entities as they
relate to the hemodialysis population.
Q 2018 by the National Kidney Foundation, Inc. All rights reserved.
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P

atients with end-stage renal disease (ESRD) who undergo maintenance hemodialysis are at signiﬁcant
risk for contracting a variety of viral infections. Alterations
in both the innate and adaptive branches of the immune
system coupled with the potential for exposure from infected blood-borne sources associated with an extracorporeal circuit predispose these individuals to infection.1 Both
hepatitis B virus (HBV) and hepatitis C virus (HCV) are of
particular interest as they have the potential for transmission via a nosocomial hematogenous spread and can ultimately cause severe liver disease.
EPIDEMIOLOGY OF VIRAL HEPATITIS
An estimated 2 billion people worldwide have been infected with HBV, and an estimated 350 million have
chronic, lifelong infections, making it a severe global public health issue.2,3 The epidemiology of hepatitis B varies
by region with increasing prevalence in North Africa, the
Middle East, parts of Eastern and Southern Europe, parts
of Latin America, and South Asia while high-prevalence
areas are seen in Western Africa and South Sudan.3,4
Between 15% and 40% of those with chronic HBV
develop cirrhosis, hepatocellular carcinoma (HCC), or
liver failure.4,5 An analysis of data from the Dialysis
Outcomes and Practice Patterns Study showed an HBV
prevalence of 0%-6.6% across dialysis facilities in
Western Europe, Japan, and the United States.5,6
Although the incidence of acute HBV has steadily
declined at an estimated rate of 80% in the United States
since the late 1980s, the incidence of HCV has increased
20% from 2015 to 2016 based on data from the Centers
for Disease Control and Prevention (CDC).7 The incidence
rate of HCV for 2016 was 1.0 case per 100,000 population,
an increase from that for 2015 (0.8 cases per 100,000 population). Actual acute cases are estimated to be 13.9 times
the number of reported cases in any year due to underre-

porting/ascertainment. The CDC estimates that 3.5 million
people are living with HCV infection in the United States.
These numbers are confounded in that many patients are
unaware of their HCV status. The number of annual
HCV-related deaths continues to rise and exceeded the
number of deaths reported for 60 other nationally notiﬁable infectious diseases combined.8 The prevalence of
HCV in the United States among patients with ESRD is reported as 8%-10% as opposed to 1.6% in the general population. Extrahepatic manifestations/complications of
HCV and increased exposure risk of hemodialysis are
identiﬁed as factors for the increased prevalence.
COMPLICATIONS OF VIRAL HEPATITIS
Viral hepatitis has been implicated as a causative factor in
the development of various forms of extrahepatic vasculitis that can lead to both acute kidney injury and chronic
kidney disease (CKD). Patients affected with HBV, particularly those with the hepatitis E antigen, have a higher
incidence of developing membranous nephropathy.9
Polyarteritis nodosa, a systemic necrotizing disorder that
affects both small- and medium-sized arteries, is associated with chronic HBV.10 Both HCV and HBV predispose
patients to developing membranoproliferative glomerulonephritis. Cryoglobulinemic vasculitis typiﬁed by the
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presence of serum proteins that precipitate in cold temperature can be caused by HCV infections. Despite treating
the aforementioned underlying disease processes, progression of chronic disease may result, ultimately leading
to dialysis dependence.
Morbidity associated with HBV and HCV ranges from
fulminant hepatic failure to a chronic carrier state that
can perpetuate transmission to others. Cirrhosis can
develop in untreated individuals and compound the
already immense burden of disease in patients with
ESRD, manifesting as encephalopathy, refractory ascites,
coagulopathy, and variceal bleeding. One study evaluating 1068 cirrhotic patients with ESRD compared with a
control group without renal diseases showed a near
doubling in hazard ratio in patients with ESRD. Oneyear and 3-year mortality rates of 48.5% and 73.1% in the
ESRD group were signiﬁcantly greater than 32.9% and
55.6% in the control group, respectively.11 In fact, liver
cirrhosis has been shown to be an independent risk factor
for death in patients, regardless of dialysis modality, as
both patients with peritoneal dialysis and hemodialysis
were found to have equivalent adverse outcomes after
adjustment for this condition.12

A–J. HBV genotypes are associated with the modes of
HBV transmission (vertical vs horizontal) and with the
risk of certain outcomes of chronic infection, such as
cirrhosis and HCC.14 Many studies have reported that
different genotypes and subgenotypes show different
geographical distributions and are related to disease
development, clinical progression, response to antiviral
treatment, and prognosis.6

ACUTE HBV INFECTION
An acute HBV infection may last up to 6 months with or
without symptoms. As the blood becomes exposed to
HBV, the body mounts a cell-mediated immune response
by sending cytotoxic T lymphocytes and natural killer cells
to the virus and releases inﬂammatory cytokines. After an
incubation period of several weeks, antiviral antibodies
appear, beginning with immunoglobulin M hepatitis B
core antibody (HBcAb).15 A window period exists in
which hepatitis B surface antigen (HBsAg) and hepatitis
B surface antibody (HBsAb) are not detected. Serologic
tests will be positive for total HBcAb and hepatitis Be antibody (HBeAb) during this time period (Fig 116). In
addition to the antibody response, a type 1 helper Tlymphocyte response occurs against hepatitis B core, surHBV PATHOGENESIS
face, and envelope antigens,
HBV belongs to the Hepadwhich helps to activate cytoCLINICAL SUMMARY
naviridae family and is a
toxic T lymphocytes and Bnoncytopathic enveloped vicell responses through a
 Hepatitis B and C have a significant impact on the care of
rus with a partially doublecytokine release.15 During
patients with end-stage renal disease, influencing
stranded circular DNA
acute HBV infections, reducinfection-control practices on a global spectrum.
genome. It can lead to a
tions in the HBV DNA load
 Both viruses have unique replication patterns and
severe liver disease such
and antigens in serum usupathogenesis
affecting
surveillance
practices,
as
fulminant
hepatitis,
ally coincide with or precede
prophylaxis, and treatment.
cirrhosis, or HCC. The pathliver damage, deﬁned by an
ogenesis of HBV-related
 Advances in antiviral therapy have led to a number of
elevated level of serum
liver disease is largely due
treatment options based on the genotype.
alanine
aminotransferase
to the immune-related liver
(ALT) and T-cell inﬁltration,
damage that is induced by
which suggests that there is
active viral replication. The small genome encodes for 4
an earlier, noncytopathic mechanism controlling HBV inmain genes by a series of overlapping reading frames.
fections.17 Potential signs and symptoms include abdomThe polymerase gene is the largest open reading frame
inal and/or joint pain, dark urine, fever, loss of appetite,
and encodes for the multifunctional polymerase protein.
fatigue, nausea, and vomiting. More severe symptoms,
The core gene encodes for the core antigen (HBcAg), and
including changes in hemodynamic status and alteration
the precore gene encodes for the hepatitis B e-antigen
of mentation, dictate the need for hospitalization as a
(HBeAg), which has a large overlapping sequence with
fulminant hepatic failure can present with encephalopaHBcAg.13 The 3 envelope genes PreS1, PreS2, and S encode
thy, or in extreme cases, cerebral edema.
for the large, middle, and small envelope proteins, respecThe CD41 T-cell response could facilitate the developtively, and the X gene encodes for the accessory X proment of neutralizing antibodies to HBsAb and the induc13
tein. HBV infection is an established cause of acute and
tion of cytotoxic T-lymphocyte responses.17 CD81 T cells
chronic hepatitis and cirrhosis. The antibody response to
contribute to the production of antiviral cytokines and
the HBV envelope antigens is a T-cell–dependent process
perform cytotoxic activities to eliminate virus-infected
and may explain why patients with advanced CKD are
hepatocytes, which not only clears HBV-infected cells
more susceptible to infections.
but also induces immunopathology. Patients with acute
HBV usually generate stronger polyclonal T-cell reHBV CLASSIFICATION
sponses against HBV antigens, especially HBV core antiGenotypic classiﬁcation of this DNA virus has become the
gen and HBeAg, than patients with chronic HBV who
standard of care as variants are produced as a result of difdeveloped only a monoclonal or even an undetectable
ferences that occur with the reverse transcriptase responT-cell response. The patient’s immune response is impersible for replication. Ten HBV genotypes have been
ative to determining whether the virus becomes a chronic
identiﬁed with an alphabetic nomenclature referred to as
infection.
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Figure 1. Acute hepatitis B serology. On average,
HBsAg can be detected after initial virus exposure. This may precede the onset of symptoms
by one to two months. Symptoms typically occur
12 weeks after exposure. HBeAg is a sign of
higher infectivity, whereas the presence of antiHBe denotes lower levels of virus with lower
infectivity. The presence of anti-HBs generally indicates recovery. There is a “window period” that
occurs when HBsAg has declined before the
appearance of anti-HBs where the only serologic
marker detectable indicating infection are IgM
anti-HBc and total anti-HBc. Note that individual
time periods may vary. Abbreviations: anti-HBe,
hepatitis B e-antibody; anti-HBs, hepatitis B surface antibody; HBeAg, hepatitis B e-antigen;
HBV DNA, hepatitis B virus DNA; HBsAg, hepatitis B surface antigen; IgM anti-HBc, hepatitis B
core IgM antibody; total anti-HBc, total hepatitis
B core antibody. Figure adapted from CDC (Centers for Disease Control and Prevention) video
clip:
https://www.cdc.gov/hepatitis/resources/
professionals/training/serology/training.htm.

CHRONIC HBV INFECTION
A chronic infection occurs when immunocompromised individuals cannot eradicate and clear infected hepatocytes.
Acute HBV progresses to chronic HBV in approximately
40% of affected patients requiring hemodialysis.2 Chronic
HBV infections seem to have diminished CD41 and
CD81 cellular responses in the peripheral blood.15 Patients
who are chronically infected are deﬁned by primarily having persistent HBsAg for more than 6 months. Associate
ﬁndings include having intermittent elevations of ALT and
aspartate aminotransferase and HBV DNA . 20,000 IU/mL.
Chronic HBV is divided into 4 phases: (1) immune tolerance; (2) immune clearance; (3) inactive carrier; and (4)
HBV reactivation.17 These phases are linked to the degree
of HBV replication and the corresponding immune
response. Initially in the immune tolerant phase, the
HBV DNA viral load is elevated but not the ALT. After
many years, when immune tolerance is lost, the
immune-clearance or active phase occurs when the immune system attacks infected hepatocytes. This results in
elevated ALT levels and ﬂuctuating HBV DNA levels
causing liver ﬁbrosis. The inactive carrier phase follows
when HBeAg is negative or low or has undetectable
HBV DNA levels with a normal ALT and does not involve
damage to the liver. The ﬁnal reactivation phase is spontaneous but can be triggered as a result of immunosuppression. Patients can revert to HBeAg positivity, but most are
HBeAg-negative with detectable DNA levels, high ALT,
and moderate-to-severe necroinﬂammation with variable
amounts of ﬁbrosis on liver biopsy. A prolonged
immune-clearance phase and HBeAg-negative hepatitis,
with persistent or recurrent hepatitis ﬂares, will eventually
result in advanced liver ﬁbrosis and increased risk of
HCC.18
HEPATITIS DELTA VIRUS
The hepatitis delta virion (HDV) is the smallest RNA pathogen known to interact with a human host and is the most

severe form of viral hepatitis. HBV plays an essential role
as a helper virus for HDV because its envelope proteins are
necessary for HDV propagation.19 HDV requires the envelope proteins of HBV for its assembly and release and
exclusively occurs in the presence of HBV.19 Therefore,
the release of HDV from the infected hepatocytes can occur
only if the cells are coinfected with HBV or when HDV superinfection occurs in individuals already infected with
HBV.19 A study in Sudan demonstrated an increased
prevalence of HDV (13.3%) among hepatitis B patients
on hemodialysis.20 Hepatitis D is transmitted through
percutaneous or mucosal contact with infectious blood
and can be acquired either as a coinfection with HBV or
as superinfection in people with HBV infections.21 A superinfection is the most common form of hepatitis D and
leads to a more severe liver disease than chronic hepatitis
B infection alone. Up to 90% of superinfected individuals
will develop chronic hepatitis D, of which approximately
70% will progress to cirrhosis, compared with 15%-30%
of those infected with HBV alone.22 There is no HDVspeciﬁc treatment. The results of pegylated interferon
alpha (IFNa) have led to unsatisfactory outcomes in
HDV-infected individuals.19 Preventative measures
including hepatitis B immunization, safe injection practices, blood safety, and harm-reduction services with clean
needles and syringes are the focus of preventing transmission of HDV.23
TREATMENT OF HBV INFECTION
Therapeutic management of HBV in dialysis patients focuses on suppression of HBV replication via antiviral therapy to prevent the development of complications
including cirrhosis and HCC.24 The decision to start antiviral therapy relies on the demonstration of active viral
replication. This can be deﬁned by HBeAg or serum
HBV DNA detectable by branched DNA or hybrid capture
assays, elevated serum ALT concentrations .1.5 times the
upper limit of normal, or evidence of moderate-to-severe
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chronic hepatitis on liver biopsy.24 The conventional cutoff
level of serum ALT for commencing antiviral therapy may
prove too high and inappropriate for dialysis patients, and
liver biopsy appears to be the only deﬁnitive means to
establish the activity of liver disease in dialysis patients.
Note that it can be difﬁcult to interpret ALT elevations in
patients undergoing dialysis as they can have a low serum
ALT level at baseline, and thus an increased ALT level in
this population may still remain in the normal range.24
Two major groups of antiviral treatments have been
licensed for the treatment of chronic HBV infection in
many countries. These include IFNa or pegylated IFNa
and nucleoside analogs (NAs) or nucleotide analogs.
Limited literature exists on IFNa therapy on patients
with chronic HBV infection receiving hemodialysis. Exacerbation of IFNa side effects, mostly myelosuppression
and malnutrition, hampers its use in clinical practice.25
The treatment options for patients with CKD are based
on NAs (lamivudine, telbivudine, and entecavir) or nucleotide (adefovir, Tenofovir disoproxil fumarate and Tenofovir alafenamide fumarate (TAF) analogs. All NAs need to
be dose adjusted in hemodialysis patients due to altered
pharmacokinetics, except TAF which is not recommended
to use in hemodialysis patients (Table 1).25 NAs are dialyzable in 50% of cases because they have low molecular
weight and relatively lack protein binding. However,
due to the high volume of drug distribution (.100 L)
and the intermittent nature of hemodialysis, no additional
dose after hemodialysis is required.26 Most NAs are given
once weekly after a hemodialysis session. For patients who
have chronic HBV and are NA-naive, the ﬁrst-line treatment recommendation is entecavir, TAF, and Tenofovir
disoproxil fumarate. Tenofovir is the NA of choice for patients with resistance to NAs. Long-term entecavir therapy
is not as effective in patients with lamivudine resistance.24,25
OCCULT HBV INFECTION
Occult HBV infection (OBI) is deﬁned as the presence of
HBV DNA in liver tissue and serum of subjects who are
seronegative for HBsAg. OBI is important in patients

with ESRD undergoing dialysis due to the transmission
of viruses through shared-use dialysis machines, frequent
blood transfusions, or by reactivation after kidney transplantation.27 Therapeutic consideration toward isolation
remains controversial. Previous reports from studies in
dialysis units have indicated that the prevalence of occult
HBV ranges from 0% to 58% among patients.28 Although
there have been no studies in the United States, there are
data demonstrating unrecognized OBI worldwide. A
study in Iranian hemodialysis patients with isolated
HBcAb showed that 50% presented with a detectable
HBV DNA. This survey showed that OBI was common
in hemodialysis patients with isolated HBcAb and could
reﬂect unrecognized OBI in hemodialysis patients. Most
of these infections are associated with low viral loads.29
A study in Palestine of the overall prevalence of OBI
among hemodialysis patients found a prevalence of
12.5%. Of the 132 hemodialysis patients tested for HBcAb,
31.8% were found to be positive.30 Ersoy and colleagues31
studied the prevalence of OBI in patients on maintenance
hemodialysis. Eighty patients who were on dialysis and
were previously detected as HBsAg negative were recruited. Sixty-eight patients (85%) tested positive for at
least 1 of the serological markers used for hepatitis B, 3 patients (3.75%) for only HBcAb, and 33 patients (41.25%) for
only HBsAb.31 The prevalence of OBI was found to be
1.25%. OBI patients are at risk for progression of liver disease, causing cryptogenic liver disease, acute exacerbation
of chronic HBV or fulminant hepatitis, poor response to
antiviral treatment, and development of HCC.24
PREVENTION OF HBV
Preventing transmission of HBV in dialysis centers has
been an important part of infection control in hemodialysis. In an environment where multiple patients receive
dialysis concurrently, repeated opportunities exist for
person-to-person transmission of infectious agents,
directly or indirectly via contaminated devices, equipment
and supplies, environmental surfaces, or hands of
personnel. Recommendations for the control of hepatitis
B in hemodialysis centers were ﬁrst published in 1977,

Table 1. Dosage Adjustment of Nucleos(t)ide Analogs and Interferon According to Serum CrCl for Hepatitis B25
CrCl
(mL/min)
$50
30-49
15-29
5-14
,5

Lamivudine

Telbivudine

Adefovir

Entecavir*

TDF

TAF

100 mg/day
First dose, 100 mg;
then 50 mg/day
First dose, 35 mg;
then 25 mg/day
First dose, 35 mg;
then 15 mg/day
First dose, 35 mg;
then 10 mg/day

600 mg/day
600 mg/day 2

10 mg/day
10 mg/day 2

0.5 mg/day
0.25 mg/day

245 mg/day
245 mg/day 2

25 mg/day
25 mg/day

600 mg/day 3

10 mg/day 3

0.15 mg/day

245 mg/day 2-3

25 mg/day

600 mg/day 3

10 mg/day 3†

0.05 mg/day†

245 mg/week†

600 mg/day 4

10 mg/week
after HD‡

0.5 mg/week
after HD‡

245 mg/week
after HD‡

Pegylated Interferon
a-2a
180 mg SQ/week
135 mg SQ/week

Abbreviations: CrCl, creatinine clearance; HD, hemodialysis; SQ, subcutaneous; TAF, Tenofovir alafenamide fumarate; TDF, Tenofovir disoproxil fumarate.
*Recommended only for nucleos(t)ide analog-naive patients.
†Recommended only for CrCl $ 10 mL/min.
‡Only for patients on HD.
Reprinted from Pipili et al,25 with permission from the International Society of Nephrology.
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and by 1980, their widespread implementation was associated with a signiﬁcant reduction in incidence of HBV infection among both patients and staff members.32
Routine preexposure vaccination should be considered
for adults who are at increased risk, such as ESRD patients
due to increased risk of percutaneous or mucosal exposure
to blood. Three HBV vaccine formulations are available,
ENGERIX-B (GlaxoSmithKline, Research Triangle Park,
NC), RECOMBIVAX HB (Merck & Co., Inc., Whitehouse
Station, NJ), and HEPLISAV-B (Dynavax Technologies
Corporation, Berkeley, CA). When ENGERIX-B and RECOMBIVAX HB are used as a 3-dose series in immunocompetent patients, more than 90% of healthy adults and
children develop adequate antibody responses. However,
patients with renal failure require larger vaccine doses: 40
mcg of RECOMBIVAX HB at 0, 1, and 6 months (3 doses)
or 40 mcg of ENGERIX-B at 0, 1, 2, and 6 months (4 doses).
HEPLISAV-B is a two-dose series given at least 4 weeks
apart in patients aged 18 years and older with all subtypes
of hepatitis B. When a vaccine series initiated with one
dose of a vaccine from a different manufacturer must be
completed with HEPLISAV-B, 3 total hepatitis B vaccine
doses should be administered. HEPLISAV-B may be
used for revaccination after an initial hepatitis B vaccine series that consisted of doses of HEPLISAV-B or doses from a
different manufacturer. Before initiating dialysis, patients’
full hepatitis B serologic status should be documented and
all susceptible patients should be vaccinated.32 The CDC
recommends an additional HBV vaccination series in the
setting of failure to seroconvert after primary vaccine for
all hemodialysis patients. Patients who fail to seroconvert
after revaccination should be retested for HBsAg. Booster
vaccination is recommended when antibody levels decline
below 10 mIU/mL.14
In addition to vaccination, other infection-control practices have been used to prevent the transmission of hepatitis B. These include segregating HBV-infected patients
in a separate treatment room, not assigning the same staff
members to care for HBV-infected and susceptible patients, and assigning dedicated dialysis equipment and
other supplies to infected patients so that these are not
used by susceptible patients. Chlorinated bleach or comparable disinfectant is used in addition to standard precautions to sterilize dialysis devices and equipment due
to the fastidious nature of the organism.
HCV CLASSIFICATION
HCV, ﬁrst identiﬁed in 1989, is an RNA, enveloped, singlestrand virus in the family Flaviviridae. Seven genotypes
have been identiﬁed and are further divided into 67 subtypes.33 Genotype 1 is the one most commonly reported
in the United States. It is highly mutagenic and historically
prone to treatment failure especially in the era preceding
the use of directly acting antiviral (DAA) therapies. Acute
presentation may be asymptomatic, and chronic disease
rate is high. The incubation period is 14-180 days with
an average of 45 days. Among newly infected persons,
20% to 30% develop symptoms of an acute disease, 75%
to 85% develop chronic infections, and 15% to 25% spontaneously clear the virus.

45

HCV TRANSMISSION
Health-care exposures remain important sources of transmission and include the following: (1) receipt of blood
products before 1992 (routine screening for HCV implemented in 1992); (2) receipt of clotting factor concentrates
before 1987; (3) long-term hemodialysis; (4) needle-stick/
sharp-object injuries; and (5) patient-to-patient transmission resulting from poor infection-control practices. Additional risk factors include incarceration, intranasal drug
use, and tattoos obtained in unregulated settings.
HCV DIALYSIS–SPECIFIC FACTORS
Extrahepatic manifestations/complications of HCV and
increased exposure risk of hemodialysis are identiﬁed as
factors for increased prevalence. Isolation is not recommended, and dialyzer reuse is not contraindicated. Unlike
HBV, no vaccine is currently available, so prevention requires strict attention to infection-control practices. Even
a single reported case of acute HCV infection or seroconversion in a hemodialysis patient warrants thorough
investigation because it might represent intrafacility transmission.34 Potential causes include lack of patient-free
period between shifts, sharing of hemodialysis machines
and multidose vials, breaches in disinfection practices,
and breaks in universal precautions.
The CDC’s reference document, “Recommendations for
Preventing Transmission of Infections Among Chronic
Hemodialysis Patients”, including the “Recommended
Infection Control Practices for Hemodialysis Units at a
Glance”, are incorporated by referring the ESRD conditions for coverage.35 The document suggests that HCV
transmission within the dialysis environment can be prevented by strict adherence to infection-control precautions
and that routine testing for ALT and anti-HCV is essential
to monitor transmission. Monthly ALT testing of HCVnegative patients is expected to facilitate timely detection
of new infections and aid in determination of when exposure or infection might have occurred. Testing for HCV
antibody (HCAb) every 6 months is also recommended
to monitor the occurrence of new HCV infections as ALT
levels are not always reliable. If unexplained ALT elevations occur, repeat HCAb testing is warranted. If unexplained ALT elevations persist in patients who
repeatedly test HCAb negative, testing for HCV RNA
should be considered. At present, HCV RNA screening
while providing a more sensitive test may not be feasible
due to economic limitations. An HCV antigen test is
pending Food and Drug Administration approval and
may replace antibody testing, should prove helpful in
posttreatment monitoring and/or serve as a more economical option to molecular testing.36 Despite the CDC’s
testing recommendations, ESRD facilities are currently
excused from the recommended testing schedule by exclusion of the HCV screening. It is important to note that the
Code of Federal Regulations was published before any
HCV treatment–speciﬁc renal studies and when use of
interferon- and/or ribavirin-supplemented HCV treatment
protocols were limited and ineffective. In 2015, the Association for Professionals in Infection Control and Epidemiology recommended removal of the HCV screening
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exclusion to the Centers for Medicare and Medicaid Services.37 A regulatory change to update the Center for
Medicare and Medicaid Services ESRD CFC’s language
regarding hepatitis C testing recommendations would be
required to remove the current exclusion and is currently
under review by the Center for Medicare and Medicaid
Services clinical standards group. HCV seroconversions
may require reporting to the local health department as
required by state-speciﬁc laws or regulations. When a
seroconversion occurs, the dialysis unit should review all
other patients’ routine laboratory test data to identify potential additional cases. Potential sources of infection
should be investigated to determine if transmission might
have occurred within the dialysis unit, including review of
the newly infected patients’ recent medical history (eg,
blood transfusion and hospitalization), history of highrisk behavior (eg, injecting-drug use and sexual activity),
and unit practices and procedures. Genomic and molecular characterization of the HCV isolates in any outbreak
should be considered,38 and increased frequency of testing
is recommended.
TREATMENT OF HCV INFECTION
HCV-positive persons should be evaluated for treatment.
They should receive education on the routes of transmission to prevent further spread of the disease and should
not donate blood. Vaccination against hepatitis A or B, if
susceptible, is recommended to prevent compounding hepatic injuries.
Historically, HCV was treated with interferon- and
ribavirin-based therapies. Owing to renal elimination,
they required signiﬁcant dose reductions. Cure rates
were low, and adverse events were high among ESRD patients. DAAs have greatly reduced the need for these aforementioned medications and impacted the management of
HCV by dramatically improving cure rates among CKD
stage 4-5 patients. DAAs target viral proteins associated
with replication, including NS3-4A protease, NS5A protein, and NS5B polymerase. Treatment algorithms generally rely on medications proven by study to achieve a
sustained viral response for the targeted genotype. Patients who have undetectable HCV RNA in the serum,
when assessed by a sensitive polymerase chain reaction
assay, 12 or more weeks after completing treatment, are
deemed to have achieved a sustained viral response. Treatment duration is variable and generally based on the medication selected, genotype, genotype resistance patterns,
and whether the patient has cirrhosis or prior HCV treatment experience. The decision to treat algorithms generally includes conﬁrmation of disease with HCV
quantiﬁcation (viral load). Patients with positive HCV
antibody but negative HCV RNA have spontaneously
cleared the infection, have been successfully treated for
HCV, or are a false-positive and do not require treatment.
Active infection conﬁrmed by a positive HCV RNA test
should be followed by genotyping. Recently “pangenotypic” therapies that can treat all major viral genotypes
have been approved by the US Food and Drug Administration.39 Patients who have failed prior DAA therapies

should be referred for reevaluation to ensure an appropriate second-line regimen is selected as advances in retreatment protocols have been reported.40
Treatment options with DAAs are dynamic. Any attempt
to provide a current treatment table would likely be
outdated before publication. The American Association
for the Study of Liver Diseases in partnership with the Infectious Diseases Society of America has established an
HCV guidance website with recommendations for testing,
managing, and treating hepatitis C. It is a highly recommended resource and should be referenced often for current practice and treatment therapies based on
individual patient proﬁle.41 A historical summary of
study-supported treatment options for patients with renal
impairment is provided in Table 239,43-50 to remove doubt
of treatment efﬁcacy within the renal population.
Estimation of the degree of liver ﬁbrosis is required for
risk stratiﬁcation, choice of DAA regimen, and follow-up
care. Liver biopsy remains the “gold standard,” but less
invasive screening is becoming more practical. Despite
having lower accuracy in assessing liver ﬁbrosis in patients
with stage 4-5 CKD than in the general population, newly
developed biochemical test panels and elastography (FibroScan; Echosens, Paris, France), an ultrasound-based
technology, are sufﬁciently reliable to evaluate extensive
ﬁbrosis/cirrhosis and preferred over biopsy with the
exception of patients with an uncertain underlying cause
of liver disease. Patients with advanced ﬁbrosis or cirrhosis
require screening for esophageal varices and HCC at the
time of diagnosis of cirrhosis. HCC screening should
continue every 6 months even after HCV is cured in patients with advanced ﬁbrosis or cirrhosis.51
In patients with decompensated cirrhosis, the use of protease inhibitor–based DAA therapies (glecaprevir, grazoprevir, paritaprevir, simeprevir, or voxilaprevir) is often
contraindicated because of possible hepatic drug accumulation and worsening liver disease. Dialysis patients with
decompensated cirrhosis should be evaluated for dual organ transplantation, and treatment decisions regarding
DAAs generally require supervised care by a transplant
physician and/or hepatologist. Patients who previously
received a liver transplant and have HCV reinfection
should be evaluated for DAA therapies and may require
alternative regimens.
Patients coinfected with human immunodeﬁciency virus or HBV require referral to an infectious disease or
liver specialist. Drug-drug interactions should be considered before treatment. HBsAg-positive patients should be
evaluated to determine if they meet criteria for antiviral
treatment of HBV, and those who do should begin treatment before starting the HCV therapy. Those who do not
meet criteria for HBV therapy should have HBV DNA
levels monitored monthly during DAA therapy and for
up to 3 months after the therapy because of the risk
that HCV treatment may cause reactivation of HBV infection. In patients with isolated HBV core antibody positivity, the risk of HBV reactivation is rare, but any increase
in ALT should prompt evaluation of HBsAg and HBV
DNA levels.
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Table 2. HCV Treatment–Specific Renal Studies
Study/Drug Regimen
42

Population Specifics

C-Surfer (Roth et al. 2015 ), elbasvirgrazoprevir

 $18 years old
 HCV genotype 1
 eGFR (MDRD)
5-29 mL/min ¼ CKD 4
,15 mL/min ¼ CKD 5 6 dialysis
 Treatment naive or experienced
 No HBV/HIV coinfection
 Compensated cirrhosis allowed

Expedition-4 (Gane et al 201743),
glecaprevir-pibrentasvir

 $18 years old
 HCV genotype 1-6
 HCV RNA $ 1000 IU/mL
 eGFR (MDRD)
5-29 mL/min ¼ CKD 4
,15 mL/min ¼ CKD 5 6 dialysis
 Treatment naive or experienced (exclusion of genotype 3 in treatment experienced)
 No HBV/HIV coinfection
 Compensated cirrhosis allowed
 Acute kidney injury excluded
 $18 years old
 HCV genotype 1-6
 HCV RNA $ 1000 IU/mL
 eGFR (MDRD) 30 to , 45 mL/min ¼ CKD
3b
5-29 mL/min ¼ CKD 4
,15 mL/min ¼ CKD 5 6 dialysis
 Treatment naive or experienced (exclusion of DAA except Sofosbuvir in treatment experienced)
 No HBV/HIV coinfection
 Compensated cirrhosis allowed
 $18 years old
 HCV genotype 1
 HCV RNA $ 1000 IU/mL
 eGFR (MDRD) , 30 mL/min 6 dialysis
 Treatment naive
 No HBV/HIV coinfection
 No cirrhosis
 $18 years old
 HCV genotype 1
 HCV RNA $ 1000 IU/mL
 eGFR (MDRD) , 30 mL/min 6 dialysis
 Treatment naive or experienced
(interferon 1 ribavirin
 No HBV/HIV coinfection
 Compensated cirrhosis allowed
 $18 years old
 HCV genotype 1a or 4
 HCV RNA $ 1000 IU/mL
 eGFR (MDRD)
5-29 mL/min ¼ CKD 4
, 15 mL/min ¼ CKD 5 6 HD
 Treatment naive
 No HBV/HIV coinfection
 No cirrhosis
 $18 years old
 Body mass index $ 18 kg/m2

Expedition-5 (Persico et al 201844),
glecaprevir-pibrentasvir

Ruby-I (Pockros et al 201645), ombitasvirparitaprevir-ritonavir and dasabuvir
with or without ribavirin

Ruby-I (cohort 2) (Vierling et al 201646),
ombitasvir-paritaprevir-ritonavir and
dasabuvir with or without ribavirin

Ruby-II (Gane et al 201647) ribavirin-free
ombitasvir-paritaprevir-ritonavir 6
dasabuvir

Magellan-2 (Reau et al 2017,48
glecaprevir-pibrentasvir

Summary
SVR-12 achieved in 99% of patients with
CKD stage 4-5 treated for HCV genotype 1
infection
 100% in treatment naive
 95% in treatment experienced
Failure to achieve SVR-12 rare and only one
relapse reported (genotype 1b)
Regimen well tolerated and efficacy
consistent across study subpopulations:
diabetes, hemodialysis, and genotype 1a
and 1b
SVR-12 achieved in 98% of patients with
CKD stage 4-5 treated for HCV infection
for all major HCV genotypes; regimen
well tolerated with a favorable safety
profile

Study regimen highly efficacious in
achieving SVR-12 in patients with chronic
kidney disease stage 3b to 5 with the
product-recommended treatment
durations based on genotype, cirrhosis
status, and prior treatment experience
Treatment was well tolerated.
Renal function remained unchanged after
treatment in the predialysis patients
assessed.

SVR-12 in 90% of patients with HCV
genotype 1 infection and stage 4 or 5
CKD.
The regimen is well tolerated; however,
ribavirin use may require a reduction or
interruption to manage anemia.
SVR-12 rate of 96% in patients with CKD
stages 4 or 5 in cohort 2; the regimen is
well tolerated; however, a large
proportion on ribavirin required dose
modification to manage anemia.

SVR-12 rate of 100% for genotype 1a and
80% for genotype 4 (n ¼ 5 one patient
terminated study due to transplant in
week 2). No virologic failure or relapse;
generally well tolerated; data support that
ribavirin may not be necessary to treat
genotype 1a or 4, but a larger trial is
required to confirm.
SVR-12 of 99%; rate surpassed historical
standard of care; well tolerated
(Continued )
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Table 2. HCV Treatment–Specific Renal Studies (Continued )
Study/Drug Regimen

HCV-Target (Saxena et al 201649);
sofosbuvir (SOF)-containing regimens
including SOF/PEG/ribavirin (RBV),
SOF/RBV, SOF/simeprevir (SMV) or
SOF/SMV/RBV

ClinicalTrials.gov NCT02251717
(Colombo et al 201750), ledipasvirsofosbuvir

Population Specifics
 HCV genotype 1-6
 Liver or kidney transplant . 3 months
prior with a stable immunosuppression
regimen
 Treatment naive or experienced with
interferon, PEG-interferon or
sofosbuvir 1 ribavirin 6 PEG
 No HBV/HIV coinfection
 No cirrhosis allowed
 $18 years old
 HCV genotype 1-6
 Longitudinal study comparing baseline
eGFR (MDRD) # 45 (n ¼ 73) mL/min with
.45 mL/min (n ¼ 1716)
 Treatment with sofosbuvir-containing
regimen for HCV
 Treatment population, regimens, dosing,
duration, or safety management guidelines undefined
 $18 years old
 HCV genotype 1 or 4
 Kidney transplant $ 6 months before
 Creatinine clearance $ 40 mL/min
 Hemoglobin $10 g/dL and
platelets . 50 K/mm3
 Treatment naive or experienced
 No HBV/HIV coinfection
 Compensated cirrhosis allowed

Summary

SVR-12 of 83% of patients with eGFR
# 45 mL/min/1.73 m2; renal clearance is
the major elimination pathway for
sofosbuvir; patients had higher rates of
anemia, worsening renal dysfunction,
and serious adverse events regardless of
the use of RBV. Patients with renal
impairment require close monitoring
with sofosbuvir-containing regimens.
SVR-12 of 100% in study population; no
need to extend therapy to 24 weeks; safe
and well tolerated; minimal change in
eGFR(Cockcroft-Gault) with median
change of 0.6 to 3 mL/min during
treatment and up to 4 weeks after
treatment

Abbreviations: eGFR, estimated glomerular filtration rate; HBV, hepatitis B virus; HCV, hepatitis C virus; HD, hemodialysis; HIV, human immunodeficiency virus; MDRD, Modification of Diet in Renal Disease; PEG, pegylated interferon; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir;
SVR-12, sustained viral response in 12 weeks.

Several studies support the safety and efﬁcacy of
DAAs after kidney transplant without increasing the
risk of acute rejection. Considerable debate has ensued
about the timing of DAA therapy in dialysis patients
awaiting transplant. Delaying treatment until after kidney transplant allows patients the opportunity to accept
an HCV-positive donor kidney and shorten kidney
transplant wait time while improving organ allocation.52 An analysis from 2010 showed that accepting
an HCV-positive organ shortened wait times by
310 days in the United States.53 As reported earlier,
cases of acute HCV infection have signiﬁcantly
increased from 2010 to 2016 along with an increase in
overdose deaths due to the opioid crisis. Transplant centers that use HCV-positive donor kidneys will likely
beneﬁt with even shorter wait times for HCV-positive
dialysis recipients. Patients who are listed at transplant
centers that do not use HCV-positive kidneys, those
with live donors, those who are not candidates for kidney transplant, or those who are not active in a center
accepting HCV-positive donor kidneys should be evaluated for treatment. In addition, patients with signiﬁcant
extrahepatic manifestations, those at signiﬁcant risk of
progressive liver disease before transplant, and those
with strong personal preference to be treated should
be evaluated for treatment with DAAs before transplantation.

SUMMARY
Chronic infection with HBV and HCV in patients with
CKD remains a distinct and challenging clinical entity.
The special characteristics of this patient group—immunosuppression, polypharmacy, and susceptibility for nosocomial transmission—coupled with complications of
progression of liver disease often have long-term implications on patient management, morbidity, and mortality. A
primary effort to eradicate these viruses with effective antivirals should be incorporated into nephrology practice
collaboratively with representatives from infectious diseases and hepatology departments. HBV immunization
is available and should be considered earlier in the course
of CKD to affect immunity and avoid nonresponse.
Appropriate and timely monitoring and screening
coupled with strict universal precautions and viral eradication should translate to lower risk for seroconversions
and improved safety of the dialysis process.
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